Hemoglobinuria - 42 Studies Found
| Active, not recruiting |
: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry : Paroxysmal Nocturnal Hemoglobinuria : 2011-04-15 |
| Completed |
: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Hemoglobinuria, Nocturnal : 2005-08-11 : Drug: Eculizumab |
| Completed |
: Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Hemoglobinuria : 2002-06-14 |
| Completed |
: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients : Paroxysmal Nocturnal Hemoglobinuria : 2010-08-30 : Drug: Eculizumab Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 da |
| Completed |
: A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2017-02-01 : Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
| Completed |
: C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients : Paroxysmal Nocturnal Hemoglobinuria : 2010-08-30 : Biological: Eculizumab Subjects were treated with open label Eculizumab and following the dose described |
| Active, not recruiting |
: An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2015-11-02 :
|
| Completed |
: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Hemoglobinuria, Nocturnal : 2016-11-01 :
|
| Completed |
: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) : Paroxysmal Nocturnal Haemoglobinuria (PNH) : 2015-09-10 : Drug: Coversin Patients enrolled in this protocol will initially be treated with an ablating dose of Cov |
| Completed |
: Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Nocturnal Hemoglobinuria PNH : 2015-08-07 : Biological: LFG316 LFG316 will be administered to all patients enrolled in the study |